Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 52.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,470 shares of the biotechnology company’s stock after purchasing an additional 10,774 shares during the quarter. Dimensional Fund Advisors LP owned 0.08% of Oramed Pharmaceuticals worth $81,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals during the 1st quarter worth $68,000. Institutional investors own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

ORMP has been the subject of several analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th. StockNews.com cut Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday.

Oramed Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ ORMP opened at $2.35 on Wednesday. The stock has a market cap of $95.48 million, a PE ratio of 9.04 and a beta of 1.77. Oramed Pharmaceuticals Inc. has a 52-week low of $1.67 and a 52-week high of $3.67. The business has a 50-day moving average price of $2.39 and a 200 day moving average price of $2.40.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.01 by $0.21. Sell-side analysts anticipate that Oramed Pharmaceuticals Inc. will post 0.24 earnings per share for the current year.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.